INDEPENDENT NEWS

Blis confirms Asia-Pacific and Africa distribution agreement

Published: Fri 7 Sep 2018 01:51 PM
Blis Technologies confirms Asia-Pacific and Africa distribution agreement with iNova Pharmaceuticals
7 September 2018 | Dunedin, New Zealand
Blis Technologies Limited today confirmed it has entered into a distribution agreement with iNova Pharmaceuticals (Singapore) Pte Ltd for the distribution of BLIS branded products. iNova Pharmaceuticals is a multinational pharmaceutical and consumer health care company that markets and sells a wide range of market-leading products in over 20 countries across Asia-Pacific and Africa.
The agreement will provide iNova Pharmaceuticals with exclusive distribution rights for BLIS branded products across Australia, Sub-Saharan Africa, and Asia based on a commitment of resources to support product launches. iNova Pharmaceutical’s presence in pharmacy retail provides a strong platform for the launch of BLIS branded products into overseas markets.
The initial focus will be on launch plans for the Australian market where BLIS K12 has achieved inclusion in TGA’s Therapeutic Goods (Permissible Ingredients) Determination for use in listed complementary medicines, allowing stronger positioning of the BLIS portfolio.
Blis CEO Brian Watson says that this agreement is another important step in the company’s finished product strategy.
“iNova Pharmaceuticals has a strong presence in the pharmacy channel and a proven track record of establishing category-leading brands in consumer health care. Working with a partner of this calibre will provide the right capability and resourcing to effectively establish BLIS branded products in multiple markets across the iNova Pharmaceuticals network. Our focus initially will be to finalise our plans for the Australian market but also to progress launch plans for other markets across Asia and Africa”
The agreement builds on the success of Blis Technologies’ new distribution relationship in New Zealand with Radiant Health, which also holds the distribution rights for the iNova Pharmaceuticals product range locally. Radiant has demonstrated its ability to leverage its presence in the market to help grow the BLIS range.
ENDS

Next in Business, Science, and Tech

Surge funding for kauri dieback and myrtle rust research
By: New Zealand Government
Spark sets 5G launch date, but without any 5G spectrum
By: BusinessDesk
Commerce Commission to appeal Steel & Tube sentence
By: Commerce Commission
Rapid rent increases a product of bipartisan inaction
By: Auckland Action Against Poverty
Turning the Tide in the Battle Against Kauri Dieback
By: New Zealand First Party
Kauri dieback and myrtle rust research to be accelerated
By: Biological Heritage National Science Challenge
New Hope for Kauri Dieback Research Programme
By: The Tree Council Inc
Emirates Team NZ To Use Spark’s 5G Network In Cup Defence
By: Spark
Rents on the rise as Govt hurts low-income families
By: New Zealand National Party
Rental Market Statistics: October Report
By: Oxygen
Indirect payment of letting fees may be unintended outcome
By: NZ Property Investors Federation
View as: DESKTOP | MOBILEWe're in BETA! Send Feedback © Scoop Media